Politics
Sen. Bill Cassidy releases report criticizing FDA oversight of abortion pill manufacturers
A Senate health committee Republican investigation claims the FDA lacks transparency and adequate oversight regarding mifepristone compliance.
The short version
- Sen. Bill Cassidy and Senate health committee Republicans released a report faulting the FDA's oversight of mifepristone manufacturers.
- The report alleges that the FDA failed to tighten restrictions on the abortion medication and improperly redacted related public records.
- The inquiry focused on the compliance practices of brand-name distributor Danco and two generic mifepristone producers.
Key facts
- Sen. Bill Cassidy and other Republicans on the Senate health committee conducted an investigation into compliance practices at Danco and two generic mifepristone manufacturers.[STAT]
- The resulting report released by Cassidy criticizes the FDA for not imposing stricter limits on mifepristone and accuses the agency of insufficient manufacturer oversight.[STAT]
- The report alleges that the FDA redacts mifepristone-related records in an unprecedented manner, leading to unanswered questions.[STAT]
What remains uncertain
- The FDA, Danco, and the generic manufacturers have not yet publicly responded to the report's allegations in the provided reporting.[STAT]